Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma

Hashim M. Aljohani; Mohamed Aittaleb; Byung Sun Park; So Ha Lee; El Mustapha Bahassi

doi:10.1158/1535-7163.TARG-17-A141

Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma

Hashim M. Aljohani
, Mohamed Aittaleb
, Byung Sun Park
, So Ha Lee
, El Mustapha Bahassi

University of Cincinnati
Korea Institute of Science & Technology (KIST)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	2
Journal	Molecular Cancer Therapeutics
Volume	17
Issue number	1
DOIs	https://doi.org/10.1158/1535-7163.TARG-17-A141
Publication status	Published - Jan 2018
Externally published	Yes

Access to Document

10.1158/1535-7163.TARG-17-A141

Cite this

@article{b04358f5a6d54c7ca244e0a8dc49b64e,

title = "Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma",

author = "Aljohani, \{Hashim M.\} and Mohamed Aittaleb and Park, \{Byung Sun\} and Lee, \{So Ha\} and Bahassi, \{El Mustapha\}",

year = "2018",

month = jan,

doi = "10.1158/1535-7163.TARG-17-A141",

language = "English",

volume = "17",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma

AU - Aljohani, Hashim M.

AU - Aittaleb, Mohamed

AU - Park, Byung Sun

AU - Lee, So Ha

AU - Bahassi, El Mustapha

PY - 2018/1

Y1 - 2018/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=hbku_researchportal&SrcAuth=WosAPI&KeyUT=WOS:000590008800130&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1158/1535-7163.TARG-17-A141

DO - 10.1158/1535-7163.TARG-17-A141

M3 - Meeting Abstract

SN - 1535-7163

VL - 17

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 1

ER -

Preclinical evaluation of a new ROS1 inhibitor to overcome resistance to EGFR therapy in glioblastoma

Access to Document

Other files and links

Cite this